Association of the TNFRSF1B rs1061622 variant with nonresponse to infliximab in ulcerative colitis

Abstract excerpt

<title>Abstract</title> <p>For severe forms of ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), biological therapies, including tumor necrosis factor inhibitors (anti-TNF), are often used. However, these drugs have a high variability in treatment response. Multiple factors, such as genetic variants, can affect this variability. The goal of the study was to verify if selected candidate variants...

Topics

Open a Topic to create a Post that cites this publication.

• Antibodies, Monoclonal
• Crohn Disease
• IL-33, ST2, and ILC Pathways
• Inflammatory Bowel Disease
• Infliximab
• Microscopic Colitis
• Receptors, Tumor Necrosis Factor, Type II
• Treatment Outcome

Identifiers and source

Literature Corpus work

3ab02112-9305-59b8-a4c8-dfb359db85ed

DOI

10.21203/rs.3.rs-3389738/v1